Skip to main content
Journal of Hematology & Oncology logoLink to Journal of Hematology & Oncology
. 2023 Jun 13;16:61. doi: 10.1186/s13045-023-01458-w

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma

Bhawana George 1,#, Suraj Konnath George 1,#, Wenyu Shi 1,2,#, Abedul Haque 1, Ping Shi 3, Ghazaleh Eskandari 1, Magnus Axelson 4, Olle Larsson 5, Ahmed O Kaseb 6, Hesham M Amin 1,7,
PMCID: PMC10265893  PMID: 37312210

Correction: Journal of Hematology & Oncology (2019) 12:80 https://doi.org/10.1186/s13045-019-0768-8

The original article [1] contains an error in Fig. 4a whereby the figure of one well that belonged to one cell line was used in another cell line.

The corrected image can be viewed ahead.graphic file with name 13045_2023_1458_Figa_HTML.jpg

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Bhawana George, Suraj Konnath George and Wenyu Shi contributed equally to this work.

Reference

  • 1.George B, George SK, Shi W, et al. Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma. J Hematol Oncol. 2019;12:80. doi: 10.1186/s13045-019-0768-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Hematology & Oncology are provided here courtesy of BMC

RESOURCES